Sotorasib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 648 publications

Divarasib Bests 1st-Generation KRASG12C Inhibitors.

Divarasib Bests 1st-Generation KRASG12C Inhibitors.

Journal: Cancer discovery

Published: October 27, 2026

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

Journal: The New England journal of medicine

Published: October 26, 2026

Food, Dietary Supplement, and Gut Microbiome Interactions in Oral Anticancer Therapy: Mechanisms, Clinical Consequences, and Management.

Food, Dietary Supplement, and Gut Microbiome Interactions in Oral Anticancer Therapy: Mechanisms, Clinical Consequences, and Management.

Journal: American journal of therapeutics

Published: October 14, 2026

Blockade of mutant RAS oncogenic signaling: A 2026 update.

Blockade of mutant RAS oncogenic signaling: A 2026 update.

Journal: Pharmacological research

Published: October 06, 2026

FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.

FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.

Journal: Science translational medicine

Published: September 30, 2026

Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC.

Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC.

Journal: JPMA. The Journal of the Pakistan Medical Association

Published: September 07, 2026

KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.

KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.

Journal: Journal of hematology & oncology

Published: September 05, 2026

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors

Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 14, 2026

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

Journal: Frontiers in oncology

Published: July 10, 2026

Showing 1-12 of 648

Last Updated: 11/08/2026